News Releases

Year

18 Oct '21

Repare Therapeutics to Participate at the H.C. Wainwright 2nd Annual Precision Oncology Conference

CAMBRIDGE, Mass. & MONTREAL, Quebec --(BUSINESS WIRE)--Oct. 18, 2021-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the H.C.

08 Oct '21

Repare Therapeutics Presents Preliminary Phase 1 Monotherapy Clinical Data from the Ongoing First-in-Human Phase 1/2 TRESR Study of RP-3500 in Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Initial TRESR data provide clinical proof of concept and validate Repare Therapeutics' SNIPRx platform for molecular selection of tumors for therapy with RP-3500 Favorable and differentiated safety profile, along with promising and distinct early activity, offer clear direction for future

07 Oct '21

Repare Therapeutics Issues Statement Regarding Inadvertent Issuance of Phase 1/2 TRESR RP-3500 Clinical Trial Abstract by the AACR-NCI-EORTC Virtual International Conference

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Oct. 7, 2021-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today issued the following statement concerning the inadvertent issuance of an abstract by the AACR-NCI-EORTC

30 Sep '21

Repare Therapeutics to Present Initial Data from the Phase 1/2 TRESR RP-3500 Clinical Trial at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Clinical Trial Selected for Oral Presentation on Friday, October 8 at 3:15 p.m. ET Preclinical Data Poster Presentation for RP-3500 Alone and in Combination with PARP Inhibitors Company Virtual Webcast Event on Friday, October 8 at 5:00 p.m. ET CAMBRIDGE, Mass.

07 Sep '21

Repare Therapeutics Appoints Thomas Civik to Its Board and as New Chairman

Former CEO of Five Prime Therapeutics brings over 25 years of leadership and commercial experience in pharma, biotech and molecular Dx CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Sep. 7, 2021-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage

02 Sep '21

Repare Therapeutics to Participate at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Sep. 2, 2021-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics,

12 Aug '21

Repare Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results

Announced dosing of first patient in Phase 1b/2 ATTACC trial of ATR inhibitor RP-3500 and PARP inhibitor combinations in patients with molecularly selected cancers Planning disclosure of initial monotherapy data from the Phase 1/2 TRESR RP-3500 clinical trial early in 4Q21 Announced dosing of first

02 Jun '21

Repare Therapeutics to Participate at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Jun. 2, 2021-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today

13 May '21

Repare Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results

Introduced PKMYT1 as synthetic-lethal target for tumors with CCNE1 amplification or FBXW7 loss and highlighted program progress at RP-6306 Virtual Investor Day Event Announced enrollment of first patient in RP-6306 Phase 1 clinical trial Activated 10 clinical trial sites across North America and

03 May '21

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--May 3, 2021-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality (SL) approach to the discovery and development of novel therapeutics,

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 17